Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration
October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.
VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.
For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html
Top resources
When no one spoke her language, she became an advocate
Doctors told Azucena Reyes she was too young for colon cancer. Now she's a Colorectal Cancer Alliance volunteer helping Spanish-speaking communities know the signs.
Bottoms Up® Celebrity Charity Event Celebrates Fifth Anniversary
The star power will be out in full force in Fairfield, CT, this September 13-14 as the fifth annual Colorectal Cancer Alliance Bottoms Up® Invitational Golf Tournament & Concert swings into action.
Never Too Young Taskforce Tackles Growing Crisis as Cases of the Deadliest Cancer Continue to Rise in People Under 50
The Colorectal Cancer Alliance's Never Too Young Taskforce of CRC patients, survivors, caregivers, and experts drives awareness and advocacy, while Project Cure CRC is accelerating research toward better treatments to help end this disease.